AOP Orphan Brings Thromboreductin to the Russian Market

The pharmaceutical company AOP Orphan is expanding its sales area for the special preparation Thromboreductin to include the large Russian market. This means that the drug, which represents an innovative treatment option for patients afflicted by Essential Thrombocythemia, is available in core Central European markets such as Austria, Hungary, Switzerland, Czech Republic and Poland as well as in Turkey, Israel, Kazakhstan and Russia. “We have started to offer our entire range of products, focusing on rare diseases, in Russia as well as the Middle East,” says Dr Rudolf Widmann, CEO of AOP Orphan. “These regions are exciting markets. Above all, this way we can open up new treatment possibilities for patients in these countries."

Essential Thrombocythemia (ET) is a rare but serious bone marrow disease, characterised by a significantly elevated blood platelet (thrombocyte) count. This considerably increases the risk of suffering a blood clot or bleeding. In cases of ET where the thrombocytes only function to a limited extent, patients suffer from bleeding in the nose, mouth, stomach and intestines. In other cases where the excessive number of thrombocytes is largely functional, patients carry with them the risk of developing life-threatening thromboses or infarctions.

Thromboreductin (active ingredient: anagrelide) lowers the blood platelet count and thereby reduces the risk of complications – without the risk of leukemogenesis as is the case with cytostatic agents. If treatment is successful, most patients with Essential Thrombocythemia have an almost normal life expectancy.